🇺🇸 MEGLUMINE ANTIMONATE in United States

28 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 20 April 2025 – 20 April 2026
• Total reports: 28

Most-reported reactions

1. Drug Ineffective — 6 reports (21.43%)
2. Off Label Use — 4 reports (14.29%)
3. Pyrexia — 3 reports (10.71%)
4. Visceral Leishmaniasis — 3 reports (10.71%)
5. Decreased Appetite — 2 reports (7.14%)
6. Dizziness — 2 reports (7.14%)
7. Gait Disturbance — 2 reports (7.14%)
8. Leukopenia — 2 reports (7.14%)
9. Myalgia — 2 reports (7.14%)
10. Tremor — 2 reports (7.14%)

Source database →

Frequently asked questions

Is MEGLUMINE ANTIMONATE approved in United States?

MEGLUMINE ANTIMONATE does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for MEGLUMINE ANTIMONATE in United States?

Marketing authorisation holder not available in our data.